Key result
EC-Pella support with empirical immunosuppression improves LVEF by ~25 percentage points in fulminant myocarditis.
Why the study?
Fulminant myocarditis is an infrequent life-threatening condition characterized by acute cardiac inflammation that can rapidly lead to cardiogenic shock, ventricular arrhythmias, or multiorgan system failure, necessitating prompt recognition and treatment.
Does combined mechanical circulatory support with VA-ECMO and Impella (EC-Pella) alongside empirical combined immunosuppressive therapy improve survival and cardiac function in a patient with suspected autoimmune fulminant myocarditis and cardiogenic shock?
Case Report (n=1)
No
Does combined mechanical circulatory support with VA-ECMO and Impella (EC-Pella) alongside empirical combined immunosuppressive therapy improve survival and cardiac function in a patient with suspected autoimmune fulminant myocarditis and cardiogenic shock?
Prompt initiation of combined VA-ECMO and Impella (EC-Pella) support alongside empirical multi-modal immunosuppression can achieve cardiac recovery and survival in rapidly progressive autoimmune fulminant myocarditis complicated by cardiogenic shock, even when histological or CMR confirmation is not feasible.
Answers are grounded in this paper and cite their sources.
May support EC-Pella plus immunosuppression when biopsy infeasible; leaves open need for prospective validation in autoimmune fulminant myocarditis.
Background: Fulminant myocarditis (FM) is an infrequent life-threatening condition characterized by acute cardiac inflammation potentially leading to severe cardiac complications such as cardiogenic shock, ventricular arrhythmias, or multiorgan system failure and therefore necessitating prompt recognition and treatment. Case presentation: This case details the rapid progression in less than 24 h of FM to cardiogenic shock in a 58-year-old female with recently diagnosed systemic sclerosis and antiphospholipid syndrome, requiring urgent mechanical circulatory support. The strategy of promptly starting venoarterial extracorporeal membrane oxygenation in combination with an Impella device for left ventricular unloading, alongside empirical combined immunosuppressive therapy was crucial for the patient’s outcome. Despite the inability to confirm diagnosis by performing an endomyocardial biopsy or cardiac magnetic resonance due to the patient's critical state, the multidisciplinary approach, including aggressive mechanical circulatory support and combined immunosuppression, led to significant improvement in cardiac function and successful weaning from support. Conclusion: This case highlights the critical importance of rapid diagnosis in the context of suspected autoimmune fulminant myocarditis to enable early initiation of targeted treatment, such as mechanical circulatory support and empirical combined immunosuppression therapy. It also underscores the benefits of a combined EC-Pella approach for left ventricular unloading when required, and the pivotal role of multidisciplinary cooperation for enhancing patient outcomes.
No takes yet. Share an insight, caveat, or question.
Magliolo et al. (2026) conducted a case report in Fulminant myocarditis and cardiogenic shock in systemic sclerosis and antiphospholipid syndrome (n=1). Combined VA-ECMO and Impella CP (EC-Pella) plus empirical immunosuppression (methylprednisolone, plasmapheresis, IVIg) was evaluated on Left ventricular ejection fraction (LVEF) recovery and survival to weaning from mechanical circulatory support. EC-Pella mechanical support and empirical immunosuppression improved LVEF from 10% to 35% and enabled weaning by day 12 in a patient with autoimmune fulminant myocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: